These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25355144)

  • 1. [Updates on Lifestyle-Related Diseases and Bone Metabolism. CKD-related osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2014 Nov; 24(11):1605-13. PubMed ID: 25355144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease and fragility fracture.
    Kazama JJ
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):46-52. PubMed ID: 28012057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder.
    Costa AG; Bilezikian JP; Lewiecki EM
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):324-9. PubMed ID: 26050118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Point of note in the treatment of osteoporotic patients complicated with chronic kidney disease].
    Inaba M
    Clin Calcium; 2016 Sep; 26(9):1277-85. PubMed ID: 27561342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Efficacy of selective estrogen receptor modulators (SERMs) in lifestyle-related osteoporosis].
    Ohta H
    Clin Calcium; 2014 Nov; 24(11):1679-87. PubMed ID: 25355152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for patients with CKD and low bone mineral density.
    Ott SM
    Nat Rev Nephrol; 2013 Nov; 9(11):681-92. PubMed ID: 24100401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of osteoporosis in chronic renal disease.
    Miller PD
    Semin Nephrol; 2009 Mar; 29(2):144-55. PubMed ID: 19371805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V; Kelepouris E; Chauhan N; Vaid M
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates in CKD-Associated Osteoporosis.
    Khairallah P; Nickolas TL
    Curr Osteoporos Rep; 2018 Dec; 16(6):712-723. PubMed ID: 30353319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone disease in CKD: a focus on osteoporosis diagnosis and management.
    Miller PD
    Am J Kidney Dis; 2014 Aug; 64(2):290-304. PubMed ID: 24726630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan].
    Taniguchi M
    Clin Calcium; 2014 Dec; 24(12):1839-44. PubMed ID: 25423930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone kidney interactions.
    Nickolas TL; Jamal SA
    Rev Endocr Metab Disord; 2015 Jun; 16(2):157-63. PubMed ID: 26156535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Increase in bone fragility from the viewpoint of bone structural properties].
    Ito M; Chiba K
    Clin Calcium; 2014 Nov; 24(11):1615-20. PubMed ID: 25355145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.
    Iwasaki Y; Kazama JJ; Fukagawa M
    Biomed Res Int; 2017; 2017():3485785. PubMed ID: 28421193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". CKD and osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2015 Sep; 25(9):1329-38. PubMed ID: 26320533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineral metabolism and cardiovascular disease in CKD.
    Fujii H; Joki N
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.